Author of

• 25929

  +

  P1.09 - Pathology (Not CME Accredited Session) (ID 941)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall

  • 26539

    +

    P1.09-36 - Clinical Significance of Cannabinoid Receptor CB2 Expression in Non Small Cell Lung Cancer (NSCLC) (ID 14370)

    16:45 - 18:00  |  Author(s): Nikolaos Kavantzas
    • Abstract
    • Slides

    Background
    

    Cannabinoid receptor CB2 expression has been identified to be high in various malignant neoplasms and it is involved in the pathophysiological mechanisms related to carcinogenesis. Lung cancer is an important health problem and new biomarkers are needed for better patients’ stratification. This study was conducted to elucidate the clinical significance of cannabinoid receptor CB2 expression in NSCLC.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    Cannabinoid receptor CB2 expression was evaluated immunohistochemically on Tissue MicroArrays (TMAs) of 79 tissue samples from NSCLC patients and it was correlated to clinicopathological parameters and overall survival (OS).

    4c3880bb027f159e801041b1021e88e8 Result
    

    79 NSCLC patients (48 adenocarcnomas and 31 squamous carcinomas) were studied. Enhanced cannabinoid receptor CB2 expression was observed in 20/79 (25.3 % ) NSCLC patients. In particular, enhanced cannabinoid receptor CB2 expression was found in 9 out of 48 (18.8%) adenocarcinomas and in 11 out of 31 (35.5%) of squamous cell carcinomas. Cannabinoid receptor CB2 expression was significantly associated with sex, smoking history and histological type (p=0.019, p=0.022 and p=0.032, respectively). In adenocarcinomas, cannabinoid receptor CB2 expression was correlated with overall survival (log-rank test, p=0.031), while there was a trend for correlation with tumor size (p=0.091) and lymph node metastasis (p=0.074). However, in squamous carcinomas cannabinoid receptor CB2 expression was not found to be significantly correlated with any of clinicopathological parameters or survival.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    Cannabinoid receptor CB2 receptor may be involved in NSCLC malignant tranformation and growth particularly in adenocarcinomas. Therefore, cannabinoid receptor CB2 receptor could be considered as a potential biomarker or a therapeutic target in NSCLC. More studies needed to elucidate the role of this molecule in NSCLC.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.